New Blood Test Flags Deadly Heart Risk in Elderly Aortic Stenosis Patients

A simple calculation from two routine blood tests may reveal which elderly patients with severe aortic stenosis are most likely to die of cardiovascular causes, according to new research published in Frontiers in Endocrinology. The study, led by Italian investigators from the Fondazione Toscana Gabriele Monasterio and the Italian National Research Council’s Institute of Clinical Physiology, examined a recently proposed biomarker called the remnant cholesterol inflammatory index, or RCII, in a cohort of 103 patients aged 75 and older with symptomatic, severe, calcified aortic valve stenosis. Their findings suggest that combining a measure of cholesterol-rich lipoprotein remnants with a marker of systemic inflammation captures a dangerous biological intersection that neither component reveals on its own.

Aortic stenosis has long been viewed as a mechanical problem: calcium accumulates on the aortic valve over decades, the valve opening narrows, and the heart struggles to push blood through. But the new study reinforces a very different picture that has been emerging over the past two decades. Degenerative aortic stenosis is an actively inflammatory process, sharing many of the same cellular and molecular players that drive atherosclerosis, including oxidized lipids, monocytes, T lymphocytes, and pro-inflammatory signaling cascades. The authors frame this within the concept of inflammaging, the chronic, low-grade, sterile inflammation that rises with age and feeds a vicious cycle accelerating structural cardiovascular changes, cardiometabolic disease, and valvular calcification simultaneously.

The RCII is designed to quantify precisely that intersection. It is calculated as the product of remnant cholesterol, the cholesterol carried in triglyceride-rich lipoprotein particles, and high-sensitivity C-reactive protein, divided by ten. Remnant cholesterol is obtained by subtracting HDL and LDL cholesterol from total cholesterol, making it derivable from any standard lipid panel. Remnant particles are considered highly atherogenic because they infiltrate the arterial intima, activate vascular and immune cells, and promote endothelial dysfunction and cholesterol deposition. C-reactive protein, meanwhile, is a hallmark of inflammaging, activating the complement system, recruiting macrophages to arterial walls, and promoting cytokine production and plaque vulnerability. Multiplying the two creates an index that reflects the joint burden of lipid-driven and inflammation-driven vascular injury.

The study population consisted of elderly patients, averaging 83.5 years of age and predominantly female, referred to the outpatient clinic of the Ospedale del Cuore in Massa, Italy, between March 2016 and March 2020. All had severe aortic stenosis with preserved left ventricular systolic function and underwent a multidisciplinary heart team evaluation including clinical, surgical, laboratory, and multidimensional geriatric assessment. The cohort carried a heavy cardiometabolic burden: 88 percent had hypertension, 74 percent had dyslipidemia, and 36 percent had type 2 diabetes. Frailty was assessed using the Fried phenotype criteria, and every patient was classified as at least pre-frail. Patients with acute heart failure, hemodynamic shock, or active infection were excluded to avoid distorting the inflammatory biomarkers under study.

The correlation analysis produced a strikingly coherent pattern. RCII levels correlated most strongly with interleukin-6, a central pro-inflammatory cytokine, with a correlation coefficient of 0.6, and also showed significant positive associations with neutrophils, the neutrophil-to-lymphocyte ratio, monocytes, platelets, erythrocyte sedimentation rate, and fibrinogen. Positive correlations, albeit weaker, emerged with glucose and creatinine, pointing toward disturbed glucose metabolism and renal involvement. The index also correlated with vascular endothelial growth factor, a mediator of the angiogenesis that occurs within calcified valves, and with frailty scores, suggesting that RCII may capture a multisystem vulnerability rather than a single disease process. Inverse correlations appeared with albumin, which typically falls during inflammatory states, and with HDL cholesterol, indicating that a high RCII reflects an unfavorable metabolic profile.

The survival findings carried the study’s most consequential implication. Over a mean follow-up of 19 months, ten cardiovascular deaths occurred. Kaplan-Meier analysis showed significantly worse survival among patients whose RCII exceeded the 75th percentile, a threshold of 17.6. In an exploratory multivariable Cox regression, higher RCII remained associated with cardiovascular mortality with a hazard ratio of 3.5, alongside elevated neutrophil counts, which showed a hazard ratio of 5.1. The authors are careful to stress, however, that the confidence interval for the RCII estimate was wide, spanning from 1.0 to 12.0, and that the small number of deaths limits statistical power. They explicitly describe the association as exploratory and hypothesis-generating rather than evidence of an established independent prognostic role.

Beneath the statistical associations lies a plausible molecular mechanism centered on the NLRP3 inflammasome, a multiprotein complex that, when activated, triggers caspase-1 and drives the release of pro-inflammatory cytokines such as interleukin-6, prompting the liver to produce C-reactive protein and fibrinogen. Oxidized LDL particles are important regulators of this inflammasome, making it a candidate link between the cholesterol pathway and vascular inflammation. In the context of aortic stenosis, NLRP3 activation promotes the transformation of valvular interstitial cells into bone-like cells, driving osteogenic calcification, and experimental studies have shown that blocking the inflammasome can reduce or reverse valve calcification in animal models. The same pathway has been implicated in frailty, sarcopenia, and cognitive decline, which may explain why a biomarker combining lipid and inflammatory signals tracked so closely with frailty in this cohort.

This mechanistic overlap also opens a therapeutic horizon. Drugs that target the NLRP3 inflammasome or its downstream interleukin-1 signaling, including anakinra, colchicine, canakinumab, and rilonacept, could in principle counteract inflammaging, atherosclerosis, and valvular calcification simultaneously. The authors also note that RCII is actionable in a broader sense, since both of its components can be modified by lipid-lowering and anti-inflammatory strategies or lifestyle changes. Yet they caution that therapies effective in atherosclerosis have not consistently shown benefit in aortic stenosis, and no pharmacological treatment currently exists to prevent or delay the progression of calcific valve disease, which is why sensitive biomarkers capable of detecting early, still-modifiable disease stages are so urgently needed.

The study has important limitations that the authors confront directly. It was retrospective, IL-6 and VEGF were measured in only 23 of the 103 patients, and the low number of cardiovascular deaths raises the risk of model instability and overfitting in the multivariable analysis. The study also cannot establish whether RCII adds predictive information beyond established clinical variables such as age, frailty, diabetes, renal function, BNP, aortic valve gradient, prior myocardial infarction, and treatment strategy. Before any clinical adoption, the authors call for external validation, standardized thresholds, serial measurements, and head-to-head comparison with established risk prediction models.

Even with those caveats, the appeal of RCII is hard to ignore. It requires no new technology, no specialized assay, and no additional blood draw, being computable from a routine lipid panel and a standard C-reactive protein measurement. Prior studies have linked the index to stroke risk, all-cause and cardiovascular mortality, metabolic syndrome, diabetes incidence, and short-term mortality in acute decompensated heart failure, with some large population analyses finding nearly sevenfold higher odds of metabolic syndrome in the highest RCII quartile. If larger prospective studies confirm the Italian team’s preliminary signal, this low-cost index could help clinicians identify which elderly patients with aortic stenosis carry the greatest hidden inflammatory-metabolic risk, opening a window for earlier, personalized prevention in a population where every month of modifiable risk matters.

Subject of Research: The remnant cholesterol inflammatory index as a predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article Title: Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article References: Mazzone, A., Gaggini, M., Foffa, I., Del Turco, S., Minichilli, F., Berti, S., & Vassalle, C. (2026). Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis. Frontiers in Endocrinology, 17, Article 1894558. https://doi.org/10.3389/fendo.2026.1894558

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1894558

Keywords: aortic stenosis, remnant cholesterol inflammatory index, inflammaging, cardiovascular mortality, C-reactive protein, frailty, NLRP3 inflammasome, cardiometabolic risk, elderly patients, biomarker, interleukin-6, valve calcification